Search Results
Your search for ASCO ,ASCO matches 21602 pages
Showing 15401 - 15450SNMMI 2016: Personalized Kidney Dosimetry Optimizes Radiotherapy Dose in Patients With Neuroendocrine Tumors
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a molecular imaging technique that allows oncologists to set patients’ radiotherapy doses right at that critical limit of delivering the most powerful dosage to neuroendocrine...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results from the SQUIRE Trial (Spanish Language Version) 
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment of patients with stage IV squamous non–small cell lung cancer. To see the English language...
SNMMI 2016: A Blood-Based Multi-Transcript Test May Predict Success of Neuroendocrine Cancer Therapy
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an investigative blood test could...
SNMMI 2016: FDG-PET Evaluates Immunotherapy for Non–Small Cell Lung Cancer
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a means of evaluating an immunotherapy that fights off non–small cell lung cancer (NSCLC) by strengthening a patient’s own immune system (Scientific Paper 134). Due to...
SNMMI 2016: CT-Based Lean Body Mass Calculations Improve Accuracy of PET for Patients With Cancer
Patients with cancer often experience significant fluctuations in weight and lean body mass. Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring lean body mass takes changes in individual body...
Many Family Physicians May Be Misinformed About Lung Cancer Screening
Although clinical trials have shown that lung cancer screening using low-dose computed tomography (CT) can detect lung cancers early and reduce lung cancer mortality, less than half of family physicians in a recent survey agreed that screening reduces lung cancer–related deaths. Most were...
Adjuvant Chemotherapy in Early-Stage Non–Small Cell Lung Cancer Improves Overall Survival
The use of adjuvant chemotherapy in early-stage non–small cell lung cancer (NSCLC) patients improves overall survival and 5-year overall survival rates in patients with tumor sizes ranging from 3 to 7 cm. These findings were published by Morgensztern et al in the Journal of Thoracic...
ASCO 2016: Nivolumab Shows Promise in Refractory, Metastatic Anal Cancer
In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University of Texas MD Anderson Cancer Center found that the immune checkpoint inhibitor nivolumab (Opdivo) shows promise for the majority of patients with squamous cell carcinoma of the ...
ASCO 2016: Hispanic and Black Young Adults With Cancer May Be More Likely to Die of Their Disease
Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a University of Colorado Cancer Center study presented by Colton et al at the 2016 ASCO Annual Meeting (Abstract 6557). The finding is...
ASCO Releases Clinical Practice Guideline on Metastatic Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Davendra P. Sohal, MD, MPH, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of patients with metastatic pancreatic cancer. Recommendations are based on expert panel systematic review of the...
ASCO Releases Clinical Practice Guideline on Treatment of Locally Advanced, Unresectable Pancreatic Cancer
As reported by Edward P. Balaban, DO, of Penn State Hershey Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on the treatment of locally advanced, unresectable pancreatic cancer. The recommendations are based on expert panel...
ASCO Releases Clinical Practice Guideline on Treatment of Potentially Curable Pancreatic Cancer
ASCO has released a clinical practice guideline on the treatment of potentially curable pancreatic cancer, as reported by Alok A. Khorana, MD, of Cleveland Clinic, and colleagues, in the Journal of Clinical Oncology. The recommendations are based on expert panel systematic review of the literature...
ASCO 2016: Nivolumab Extends Survival for Patients With Advanced Renal Cell Carcinoma Treated Beyond Disease Progression
In a large randomized study, the immunotherapy drug nivolumab (Opdivo), an anti–PD-1 (programmed cell death protein 1) monoclonal antibody, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. Results ...
ASCO 2016: Cancer Diagnosed More Often in Patients With Primary Immunodeficiency Disease
Primary immunodeficiency disorders are a group of more than 300 single gene defects that affect the role of the immune system and prevent it from functioning properly. When Roswell Park Cancer Institute (RPCI) researchers evaluated the overall and site-specific incidence of cancer among patients...
Scenes From ASCO 2016
1. “The Bean” or Cloud Gate with a little ASCO color. Photo © 2016 ASCO/Todd Buchanan. 2. ASCO CEO Allen S. Lichter, MD, FASCO, introducing ASCO President Julie M. Vose, MD, MBA, FASCO, during the Opening Session of the 2016 ASCO Annual Meeting in Chicago. Photo © 2016 ASCO/Phil McCarten....
FDA Approves EGFR Mutation–Detecting Blood Test for NSCLC
The U.S. Food and Drug Administration (FDA) recently approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva). This is the first FDA-approved, blood-based genetic test that can detect EGFR gene...
MD Anderson Receives $10.6 Million From CPRIT for Lung Cancer Research
The University of Texas MD Anderson Cancer Center will receive $10.6 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT) for two collaborative studies targeting crucial issues in lung cancer. The two multi-investigator research awards, designed to support teams of...
FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has approved Netspot, the first kit for the preparation of Ga-68 dotatate injection, a radioactive diagnostic agent for positron-emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with...
ASCO Value in Cancer Care Task Force
The Value in Cancer Care Task Force was established in 2007 to educate oncologists about the importance of discussing costs associated with recommended treatments, empower patients to ask questions about the anticipated costs of their treatment options, identify the drivers of the rising costs of...
ASCO Updates Value in Cancer Care Framework
On May 31, 2016, ASCO published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al,1 defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms...
Yale Researchers Win Sokoloff Family-Melanoma Research Alliance Award
A new approach to understanding why T cells are often too weak to fight and destroy tumor cells has earned Yale Cancer Center researchers team science award from the Sokoloff Family-Melanoma Research Alliance. The $900,000 award will fund research over 3 years examining metabolic regulation of ...
Philip A. Salem, MD, Honored by President of Mexico for Cancer Care
Oncologist Philip A. Salem MD, Director Emeritus of Cancer Research at Baylor St. Luke’s Medical Center in Houston, was honored as a physician and author on April 28 by the President of Mexico Enrique Peña Nieto and his government for Dr. Salem’s lifelong commitment to cancer care worldwide. Dr....
AUA Honors Its 2016 Annual Award Winners
The American Urological Association (AUA) honored its 2016 AUA award recipients during its 111th Annual Meeting in San Diego, Calfornia. These physician researchers, educators, and organizations were honored for their contributions to the field of medicine, the specialty of urology, and the AUA....
Cheryl Taylore Lee, MD, Named Urology Chair at The Ohio State University Wexner Medical Center
The Ohio State University Wexner Medical Center has named a prominent expert in bladder cancer, Cheryl Taylore Lee, MD, to lead its urology, uro/gynecology, and uro/oncologic programs, beginning July 1, pending approval by The Ohio State University Board of Trustees. Dr. Lee will be Chair of the...
An Unusual Memoir of Cancer
“A book about the future must be written in advance. Later I won’t have the energy. So I will do it now.” So begins The Iceberg, a memoir set in Britain of a woman, Marion Coutts, whose husband was diagnosed with a brain tumor, which eventually killed him. Unfortunately, cancer memoirs flood the...
University of Maryland Greenebaum Cancer Center Designated as NCI Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Cancer Center has been awarded the National Cancer Institute’s (NCI’s) highest designation as a Comprehensive Cancer Center. The prestigious distinction recognizes the cancer center’s high caliber of scientific leadership and robust programs ...
Dana-Farber President to Receive SPARK! Award for Health Promotion
The Albert Schweitzer Fellowship (ASF) announced its selections for the 2016 SPARK! Awards. Edward J. Benz, Jr, MD, President and CEO of Dana-Farber Cancer Institute, will receive the 2016 Schweitzer Clarion Award for Health Promotion and Education. Dr. Benz is being honored for bringing...
HOPA Research Grants Announced, Totaling Nearly $60,000 in Funding
The Hematology/Oncology Pharmacy Association (HOPA) has awarded two HOPA Research Grant Awards to Val Adams, PharmD, BCOP, FCCP, and Jill S. Bates, PharmD, MS, BCOP, for their respective research projects. The goal of HOPA’s Research Grant efforts are to fund work that results in facilitating...
Low-Dose Chemical Exposure and Cancer
According to estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), environmental toxic exposures are responsible for between 7% and 19% of human cancers. However, the 2008–2009 President’s Cancer Panel Annual Report estimated that the “true...
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Clinical Trials Actively Recruiting Patients With Liver Cancer
Pilot Study Title: Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma Study Type: Interventional/nonrandomized/parallel assignment Study Sponsor and Collaborators: Washington University School of Medicine Purpose: ...
Multi-Institutional Metastatic Melanoma Research Team Receives $900,000 L’Oréal Paris USA–MRA Team Science Award for Women in Scientific Research
An international, multi-institutional research team consisting of the Spanish National Cancer Research Centre (CNIO); The Wistar Institute; Cancer Research UK Edinburgh Centre; the Perelman School of Medicine at the University of Pennsylvania; and the Icahn School of Medicine at Mount Sinai has...
SIRIUS Trial Heralds a New Era of Promise in Treating Resistant Myeloma
Multiple myeloma cells uniformly overexpress CD38.1 Daratumumab (Darzalex), a CD38-targeting human IgG1 kappa monoclonal antibody, has been evaluated in a series of phase I/II trials involving patients with relapsed or relapsed and refractory myeloma who have received at least two or more prior...
American Cancer Society Report Assesses Progress Against Goals Set for Nation 25 Years Ago
A new report assesses how the nation fared against the ambitious goal set by the American Cancer Society (ACS) to reduce cancer death rates by 50% over 25 years ending in 2015. The report finds areas where progress was substantial, and others where it was not. Published by Byers et al,1 the report ...
ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships
ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately...
Prostate Cancer: Opinions Vary on Gleason Scores and Surgery
Diagnosis and treatment of prostate cancer have been the source of heated debate for decades, most of which has centered on the clinical value of the prostate-specific antigen (PSA) test. In 2012, the U.S Preventive Services Task Force (USPSTF) gave the PSA test a D grade, which discourages many...
Newly Updated: Resources to Help Your Patients Quit Tobacco
Most smokers and other tobacco users want to quit. ASCO’s patient booklet Stopping Tobacco Use After a Cancer Diagnosis offers people with cancer and their caregivers information on tobacco cessation. With information on treatments and resources available, this booklet gives patients the practical...
2016 ASCO Annual Meeting Planning Committees
The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with nearly 30,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees and thank them for their time and...
ASCO Submits Comments to ONC on Enhanced Oversight of the HIT Certification Program
On Monday, May 2, ASCO submitted comments to the Office of the National Coordinator (ONC) regarding the proposed Enhanced Oversight of the ONC Health Information Technology (HIT) Certification Program rule. The rule would increase ONC oversight of certified health IT, define a process for...
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as well as localized disease (Abstracts 5001, 5003, 5023, and 5021).
Lung Cancer Alliance Supports Two Young Investigator Awards
The Conquer Cancer Foundation of ASCO (CCF) has received generous support from Lung Cancer Alliance to fund a 2016 and 2017 Young Investigator Award (YIA) in lung cancer. Lung Cancer Alliance has a more than 20-year history of working to save lives and advance research by empowering those living...
Peter H. Wiernik, MD, Receives 2016 Walter Reed Distinguished Achievement Award From UVA Medical
The University of Virgina (UVA) Medical Alumni Association has recognized Peter H. Wiernik, MD, as co-recipient of its 2016 Walter Reed Distinguished Achievement Award. Dr. Wiernik received the award along with Charles W. Cummings, MD, former Chair of the Department of Otolaryngology–Head and Neck ...
Stephen K. Burley, MD, DPhil, Named Co–Program Leader at Rutgers
Stephen K. Burley, MD, DPhil, has been named as Co–Program Leader of the Cancer Pharmacology Research Program at Rutgers Cancer Institute of New Jersey. This basic science program unites investigators with broad scientific expertise who share a strong interest in cancer pharmacology and preclinical ...
PALOMA-3 Trial in HER2-Negative Metastatic Breast Cancer: Challenge of Moving Beyond Estrogen Receptor Positivity
Hormone receptor–positive breast cancer represents the largest therapeutic subgroup of the disease. The development of endocrine therapies has shaped the treatment paradigm for both advanced- and early-stage disease for decades.1 Still, despite their significant impact, advanced breast cancer...
QOPI Certification Program Certifies First International Practice
ASCO recently announced that the Contemporary Oncology Team of Athens, Greece, as part of the new international pilot project, is the first international practice to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC (QCP). “Achieving...
Learning About Fertility Is Important to Young Patients With Cancer
It is more and more common for people to wait until their 30s or 40s to have children. Consequently, many young adults have not completed their desired childbearing when they are diagnosed with cancer. Cancer treatments can impair fertility directly (usually via gonadotoxicity from chemotherapy,...
Richard J. O’Reilly, MD, Named The Society of MSK’s Inaugural Prize Winner for Groundbreaking Contributions in Pediatric Oncology
The Society of Memorial Sloan Kettering Cancer Center (MSK) has announced that Richard J. O’Reilly, MD, has been named the inaugural recipient of The Society of Memorial Sloan Kettering Prize. Founded in 1946, The Society of MSK is a volunteer-led organization within MSK dedicated to promoting the ...
Patient Advocate Michael Kaplan to Lead Melanoma Research Alliance
The Melanoma Research Alliance (MRA), the world’s largest private funder of melanoma research, has named Michael Kaplan as its new leader. For the past 20 years, Mr. Kaplan has headed various nonprofits and patient advocacy groups, including his most recent position as President and CEO of...
AACR CEO Margaret Foti, PhD, MD (hc), Honored With Ovarcome Excellence Award
Margaret Foti, PhD, MD (hc), Chief Executive Officer (CEO) of the American Association for Cancer Research (AACR), has received the Ovarcome Excellence 2016 Award in recognition of her accomplishments in the field of cancer research, and her commitment to increasing public awareness about cancer...
Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy in hematologic malignancies (Abstracts 7503, 7504, and 7505).
